DRG Market Assessment reports

Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…

In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…

In 2022, sales of branded biologics in immunology exceeded $67 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under…

In 2022, sales of branded biologics in ophthalmology exceeded $9.8 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast period…

*Key drugs covered: *Admelog / Insulin Lispro Sanofi, Aranesp, Avastin, Basaglar / Abasaglar, Enbrel, Herceptin, Herzuma, Hulio, Humalog, Humira,Inflectra, Kanjinti, Neulasta, Neupogen, Nivestim /…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…

China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…